CAR-T Cell Therapy in China: How It Works, What's Approved, and What It Costs
A living drug made from your own cells, engineered to find and destroy your cancer. Here is what CAR-T therapy actually is, which products are approved in China today, who qualifies, and what the real risks are — in plain language, with sources.
Medically informed overview, last checked October 2026. This page is educational and does not replace a consultation with a licensed oncologist.
What is CAR-T cell therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a type of cellular immunotherapy. Doctors collect a patient's own T-cells (a type of white blood cell) through a process called apheresis, then genetically engineer those cells in a laboratory to carry a synthetic receptor on their surface. That receptor is built to recognize a specific protein marker on cancer cells — for example, CD19 on certain B-cell lymphomas and leukemias, BCMA on multiple myeloma cells, or CLDN18.2 on some gastric cancer cells.
The engineered cells are grown into the hundreds of millions, then infused back into the patient. Once inside the body, these "living drug" cells can multiply further, seek out cells carrying the target marker, and destroy them — a mechanism fundamentally different from chemotherapy or targeted small-molecule drugs, which do not adapt or multiply on their own.
In one sentence
CAR-T therapy re-engineers a sample of your own immune cells into a targeted, self-replicating treatment against your specific cancer, manufactured individually for each patient over roughly one to three weeks.
How the process works, step by step
Apheresis (cell collection)
Blood is drawn through a machine that separates and collects T-cells, then returns the rest of your blood to your body. Takes 3–4 hours.
Genetic engineering
In a GMP-certified lab, a disarmed viral vector inserts the CAR gene into your T-cells, reprogramming them to recognize your cancer's target marker.
Expansion
Engineered cells are grown in bioreactors until there are enough — often hundreds of millions — to be an effective dose.
Lymphodepleting chemotherapy
A short course of low-dose chemotherapy reduces competing immune cells, so the CAR-T cells can expand more effectively once infused.
Infusion
The engineered cells are infused back into your bloodstream — a short, usually painless procedure similar to a blood transfusion.
Monitoring
1–2+ weeks of inpatient monitoring for cytokine release syndrome and neurological side effects, which typically emerge in the first 7–14 days.
CD19, BCMA, CLDN18.2: what "target" means and why it matters
Every approved CAR-T product is built against one molecular target. Your cancer has to express that target for the therapy to have a mechanism of action at all — this is usually confirmed by a pathology report your reviewing physician will ask for.
- CD19 — expressed on most B-cell lymphomas and B-cell acute lymphoblastic leukemia. The most mature CAR-T target, with the longest track record and the largest number of approved products worldwide.
- BCMA (B-cell maturation antigen) — expressed on plasma cells, the cell type that becomes malignant in multiple myeloma. Approved for relapsed/refractory myeloma after multiple prior treatment lines.
- CLDN18.2 (Claudin 18.2) — expressed on a subset of gastric and gastroesophageal junction adenocarcinomas. In June 2026, a CLDN18.2 CAR-T became the first CAR-T therapy approved anywhere in the world for a solid tumor, a milestone that had eluded CAR-T developers for years because solid tumors are structurally harder for engineered T-cells to penetrate than blood cancers.
NMPA-Approved CAR-T Therapies in Mainland China (2026)
Compiled from public NMPA approvals and manufacturer disclosures. Prices are published list / patient-assistance-programme prices converted from CNY at approximately US$1 = ¥7.2 for illustration only — they are not a quotation and do not include hospitalization, workup or monitoring. Ask us for a current, itemized quotation for your specific diagnosis.
| Product (generic / brand) | Manufacturer | Target | Approved for | List price (USD, approx.) | Patient-assistance price (USD, approx.) |
|---|---|---|---|---|---|
| Axicabtagene ciloleucel (Axi-cel) |
Fosun Kairos (formerly Fosun Kite) | CD19 | Large B-cell lymphoma, 2nd line+ (adult) | ~$166,700 | ~$111,100 |
| Relmacabtagene autoleucel (Relma-cel) |
JW Therapeutics | CD19 | R/R large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma (≥2 prior lines) | ~$179,200 | ~$130,600 |
| Ranicabtagene autoleucel (Hengkailai) |
Shanghai Hengrun Dasheng Biotechnology | CD19 | R/R large B-cell lymphoma (≥2 prior lines) | ~$124,900 | ~$76,400 |
| Inaticabtagene autoleucel (Yuanruida) |
Juventas Cell Therapy | CD19 | R/R B-cell ALL (adult); R/R large B-cell lymphoma (≥2 prior lines, added 2025) | ~$138,750 | ~$83,300 |
| Pujiaolunsai (Pulidekai) | Chongqing Precision Biotech | CD19 | CD19-positive R/R B-cell ALL, ages 3–21 | Quotation on request | — |
| Equecabtagene autoleucel (Fukesu) |
IASO Biotherapeutics | BCMA | R/R multiple myeloma, 4th line+ (≥3 prior lines incl. PI & IMiD) | ~$162,000 | ~$133,300 |
| Zevorcabtagene autoleucel (Saikaize) |
CARsgen Therapeutics / Huadong Medicine | BCMA | R/R multiple myeloma, 4th line+ (≥3 prior lines incl. PI & IMiD) | ~$159,700 | — |
| Satricabtagene autoleucel (Kailimei) |
CARsgen Therapeutics | CLDN18.2 | CLDN18.2+/HER2- advanced gastric or GEJ adenocarcinoma, after ≥2 prior lines (approved June 2026) | ~$137,500 | — |
A ninth product has also received NMPA approval per 2026 industry reporting; we update this table as new approvals and pricing disclosures are confirmed. R/R = relapsed or refractory. PI = proteasome inhibitor. IMiD = immunomodulatory drug. See Cost & Financing for all-in treatment cost ranges including hospitalization.
Who typically qualifies?
CAR-T therapy is approved for defined situations, not as a first-line, universal treatment. Across the products above, eligibility generally requires:
- A confirmed diagnosis matching an approved indication (e.g., relapsed/refractory large B-cell lymphoma, B-ALL, multiple myeloma, or CLDN18.2-positive gastric cancer).
- Prior standard treatment that has already failed, stopped working, or relapsed — the specific number of required prior lines varies by product and is listed in the table above.
- Adequate organ function (heart, lungs, kidneys, liver) and a performance status well enough to tolerate lymphodepleting chemotherapy and potential side effects.
- No uncontrolled active infection or other condition that would make apheresis or inpatient monitoring unsafe.
This is exactly what our free medical record review is designed to assess before you commit to travel. We would rather tell you "not a candidate, and here is why" than have you spend money to be turned away in China.
Risks and side effects you should know about
CAR-T therapy is powerful precisely because the engineered cells are highly active once infused — which also means real, well-documented risks:
- Cytokine release syndrome (CRS) — an inflammatory reaction as CAR-T cells activate and multiply, causing fever, low blood pressure and, in severe cases, organ stress. Usually manageable with medication (including tocilizumab) under inpatient monitoring.
- Neurological effects (ICANS) — confusion, difficulty speaking, tremor or, rarely, seizures, typically in the first one to two weeks and usually reversible with prompt treatment.
- Prolonged low blood counts and infection risk — from both the lymphodepleting chemotherapy and the CAR-T cells' effect on normal B-cells.
- Long-term monitoring for secondary cancers — regulators including the US FDA have asked manufacturers of several CD19/BCMA CAR-T products to monitor for rare secondary T-cell malignancies; this is why we build lifelong follow-up into every treatment plan, not just the first 100 days.
A response is not guaranteed
Published trial data shows the majority of appropriately selected patients respond to CD19 and BCMA CAR-T therapy, with a meaningful share achieving durable remission — but not every patient responds, and not every response lasts. Ask your reviewing physician for the specific trial data behind the product recommended for you, and treat any "near-certain cure" claim from any provider, anywhere, with skepticism.
How CAR-T compares to other options
| Approach | How it works | Typically considered when |
|---|---|---|
| Chemotherapy | Non-specific drugs kill rapidly dividing cells | First-line treatment for most blood cancers; often required as "bridging" before CAR-T |
| Stem cell transplant | Replaces bone marrow with donor or own stem cells after high-dose chemo | Eligible patients in remission, especially where a matched donor is available |
| CAR-T cell therapy | Engineered autologous T-cells targeting a specific cancer marker | Relapsed/refractory disease after standard options, matching an approved indication |
| CAR-T abroad vs. at home | Same mechanism; differs in approved products, manufacturing turnaround and price | When a needed product isn't approved, is on a long waitlist, or is priced out of reach at home |